NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- State
- Under way
- Phase
- Phase 3
- People
- 338 planned
- Started
- 9 Mar 2023
- Primary completion
- Dec 2027
- Arms
- Lebrikizumab, Lebrikizumab - Optional Extension Period (OEP)
- Results
- None posted
- 21 Feb 2023: Trial registered
- 9 Mar 2023: Trial started